Skip to content

Delcath Systems DCTH Free cash flow

Free cash flow at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
$24.67M+26.5%
Boston Scientific logo
Boston ScientificBSX
$171M-51.7%
Altimmune logo
AltimmuneALT
-$20.96M
Wave Life Sciences logo
Wave Life SciencesWVE
-$59.99M+5.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$229.43M-11,360%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Calculated from Delcath Systems’s reported figures.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's free cash flow?
Delcath Systems (DCTH) reported free cash flow of $287K in Q1 2026.
How has Delcath Systems's free cash flow changed year-over-year?
Delcath Systems's free cash flow decreased by 86.1% year-over-year, from $2.06M to $287K.
What is the long-term trend for Delcath Systems's free cash flow?
Over 4 years (2021 to 2025), Delcath Systems's free cash flow has grown at a -2.0% compound annual growth rate (CAGR), from -$22.75M to $20.97M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.